Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06350903Not ApplicableCompleted

Suppression With Empagliflozin as an Alternative To High-Fat Low-Carbohydrate Diet for Myocardial F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Imaging

Role: lead

NCT07099404Not Yet Recruiting

Parathyroid Adenoma Detection With Rubidium-82 Imaging

Role: lead

NCT06332456Completed

Assessment of Renal Microcirculation With Rubidium Positron Emission Tomography

Role: lead

NCT07087210Active Not Recruiting

In Vivo Quantitative Mapping of Mitochondrial Cardiac Membrane Potential in Heart Failure

Role: lead

NCT06353009Not ApplicableCompleted

Effect of a Single Ultra-Processed Meal on Myocardial Endothelial Function Assessed With Positron Emission Tomography

Role: lead

All 5 trials loaded